Melbourne, Australia, and Utrecht, the Netherlands, 8th November 2016 – AdAlta Limited (ASX: 1AD), a biotechnology company specialising in the discovery and development of protein-based therapeutics, and Crossbeta Biosciences,
Author: Crossbeta
Probiodrug and Crossbeta Bioscience enter into a strategic partnership in the field of Alzheimer’s disease biomarker
HALLE (SAALE), Germany, UTRECHT, The Netherlands, 30 June 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD),
Crossbeta receives grant from the Michael J. Fox Foundation to develop alpha-synuclein oligomer-specific antibody
April 18, 2016 – Utrecht, The Netherlands Crossbeta Biosciences today announced that it received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in the amount of USD 425,000 for the development of an alpha-synuclein oligomer-specific antibody.
Crossbeta and Servier announce strategic oligomer-based research collaboration in neurological diseases involving misfolded proteins
Utrecht, The Netherlands and Suresnes, France, October 5, 2015 – Crossbeta Biosciences and Servier today announced their collaboration in several research projects involving the use of Crossbeta’s technology for generating stable oligomers.
Crossbeta completes financing round and secures Innovation Grant
Utrecht, The Netherlands, July 12, 2015 – Crossbeta Biosciences today announced that it has completed a round of internal financing. In addition, the company secured another Innovation Grant from the Dutch government agency RVO for the further development of Crossbeta’s platform technology and stable oligomers in the field of Alzheimer’s, Parkinson’s, ALS and Huntington’s disease.
Crossbeta to supply PerkinElmer stable oligomers for use as AlphaLISA® analytes
February 22, 2015 – Utrecht, The Netherlands Crossbeta Biosciences today announced that PerkinElmer, Inc. has chosen Crossbeta’s stable oligomers for inclusion as reference standards in certain AlphaLISA® Research Immunoassay kits. The relationship has been initiated by joint activities on beta-amyloid 1-42-related applications with the option to expand to other protein oligomers.
Crossbeta and AdAlta collaborate to find antibody for Alzheimer’s disease
December 1, 2013 – Utrecht, The Netherlands & Melbourne, Australia Read the full press release here (pdf). Today, Crossbeta Biosciences and AdAlta announced that they have established a collaborative relationship in which AdAlta will deploy its i-body technology to develop oligomer-specific i-bodies for therapeutic and diagnostic applications in Alzheimer’s disease using Crossbeta’s stabilized beta-amyloid oligomers.
Crossbeta Biosciences secures funding for the development of its drug screening platform
Utrecht, The Netherlands, March 3rd, 2013 – Today, Crossbeta Biosciences announced that it has successfully secured funding to execute its plans for the next years. This financing round is based on investments by new as well as existing shareholders and includes an Innovation Grant from AgentschapNL.
Crossbeta Biosciences, Good Biomarker Sciences and U-Protein Express join forces to develop Alzheimer’s disease biomarker with a grant from IPC-BioFarmind
Utrecht & Leiden, The Netherlands, January 27, 2012 – Three Dutch biotech companies with complementary activities and expertise announced today that they will collaborate to develop a biomarker assay for Alzheimer’s disease. This initiative is awarded with a grant from IPC-BioFarmind.
Crossbeta welcomes Professor Philip Scheltens as scientific advisor
Professor Philip Scheltens, MD, PhD, is an internationally renowned Alzheimer researcher, Full Professor of (Cognitive) Neurology and Director of the Alzheimer Centre, VU University Medical Center Amsterdam, Amsterdam, The Netherlands. For more information, go to scientific advisors.